- As China Slows Down, the Philippines Moves to Grab Foreign Investment
- Why Obamacare Subsidies Should Be Struck Down by the Supreme Court
- MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter
- Shale Oil Bust Enters Phase Two, Led by Hercules and SandRidge
- Comcast Wants Congress to Gut the New Net Neutrality Rules
For investors still cringing at their IRAs, 401(k)s or taxable mutual funds and exchange-traded funds, are you ready to take a chance on the companies that have brought you so many unhappy returns?
The regionals may not have as much recognition as the mammoth securities firms, but they won't be receiving as many unwanted headlines either.
If Pfizer's looking for the next Lipitor, it probably hasn't found it with the acquisition of Wyeth.
Allergan, Mentor and Medicis have struggled in the past year, but if the economy improves, share prices could, too.
When it comes to investing in big pharmaceutical stocks, it's hard to top this company, especially as its peers continue to suffer.
The company continues to wrestle with the dilemma surrounding the drugs Premarin, Prempro and Premphase. Plaintiffs' lawyers have filed approximately 5,400 lawsuits.
In the past five years, its stock has more than tripled, easily outperforming the S&P 500 and the Amex Index of large drug stocks. Is anyone paying attention?
Shares of most major generic-drugmakers have traded below the S&P 500 for the 12 months ended May 23, and that index was off nearly 10%.
Companies such as C.R. Bard and Becton Dickinson might not be the most glamorous names, but their slow and steady performances may win the race.
The companies that supply the tools needed for pharma research and development often profit no matter the success of a drug trial.